Roche has stopped a pair of phase 3 Alzheimer’s disease trials after an interim analysis found they were unlikely to hit their primary endpoint. The setback wipes out near-term hopes of getting the AC ...
LAUSANNE, Switzerland, Oct. 04, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today ...
Mayo Clinic Jacksonville researchers report evidence to suggest that prevention of amyloid beta (Abeta) deposition in the brain prior to Alzheimer's disease (AD) onset may be easier than curing ...
Credit: Getty Images. The designation was supported by initial interim safety and immunogenicity data from the phase 1b/2 ABATE trial. The Food and Drug Administration (FDA) has granted Fast Track ...
The beta amyloid peptide (Abeta) is the primary component of the senile plaques observed in the brains of Alzheimer's patients, and this peptide is toxic to neurons and other cells in many different ...
LAUSANNE, Switzerland, March 16, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative ...
WASHINGTON — New research points to tau, not amyloid-beta (Abeta) plaque, as the seminal event that spurs neuron death in disorders such as Alzheimer's disease. The finding, which dramatically alters ...
Results of a new study challenge the findings of previous work on the initial aggregates formed by amyloid beta, a protein closely associated with the onset and development of Alzheimer’s disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results